Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened

Executive Summary

Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.

You may also be interested in...



Former US FDA Commissioners Try To Shake Loose Biden Nomination

Acting commissioner Janet Woodcock, a candidate for the permanent job, and agency’s career staff also garner the group's compliments.

Former US FDA Commissioners Try To Shake Loose Biden Nomination

Acting commissioner Janet Woodcock, who is up for the permanent job, as well as the agency’s career staff also garner the group's compliments.

Former US FDA Commissioners Try To Shake Loose Biden Nomination

Acting commissioner Janet Woodcock, a candidate for the permanent job, and agency’s career staff also garner the group's compliments.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel